Author:
Elsaadany Hossam M.,Almaghraby Mohammed F.,Edrees Awatif A.,Elsherbiny Yasser M.,Kumar Roobina K.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Watanabe T, Aoyagi K, Nimura S, Eguchi K, Tomioka Y, Sakisaka S. New fecal biomarker, α1-acid glycoprotein, for evaluation of inflammatory bowel disease: comparison with calprotectin and lactoferrin. Med Bull Fukuoka Univ 2013; 40: 155–162.
2. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894–1899.
3. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780–787.
4. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426–431.
5. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40–46.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献